Adult
CDC Expands RSV Vaccine Recommendations for Adults 75 and Older
RSV vaccine, CDC, adults 75 and older, vaccination recommendations, public health
Merck’s Capvaxive: FDA Approves First Pneumococcal Vaccine Designed for Adults
Merck, Capvaxive, FDA Approval, Pneumococcal Vaccine, Adults, Pneumonia, Invasive Pneumococcal Disease
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy
FDA Grants Accelerated Approval to Madrigal’s Rezdiffra for MASH Treatment
FDA approval, Madrigal Pharmaceuticals, Rezdiffra (resmetirom), Metabolic dysfunction-associated steatohepatitis (MASH), Accelerated clearance, Adult patients with non-cirrhotic MASH and moderate-to-advanced liver fibrosis